Search for a trial

A placebo-controlled, double-blind, randomized trial to compare the effect of treatment on plaque burden as determined by intravascular ultrasound and to evaluate the efficacy, pharmacokinetics, safety, and tolerability of MDCO-216 given as multiple weekly infusions in subjects with a recent acute coronary syndrome.

Primary ObjectivesTo evaluate the effect of MDCO-216 treatment on the change in PAV of a target coronary artery as measured by IVUS imaging following five weekly infusions of MDCO-216 (20 mg/kg) compared with placebo in subjects with a recent ACS.…

Proof-of-pharmacology clinical trial on a vaccine that elicits a protective humoral immune response against oxidized low density lipoprotein

The aim of the present study is to determine the effect of vaccination on anti-oxLDL antibodies in man.

A placebo-controlled, double-blind, randomized trial to compare the effect of different doses of ALN-PCSSC given as single or multiple subcutaneous injections in subjects with high cardiovascular risk and elevated LDL-C.

PRIMARY OBJECTIVE The primary objective of this study is to evaluate the effect of ALN-PCSSC treatment on LDL-C levels at Day 180. SECONDARY OBJECTIVESThe secondary objectives of this study are to evaluate the effect of ALN-PCSSC on the following…

Effects of ivabradine on vascular function in individuals at increased risk of developing cardiovascular disease and with impaired endothelial function;An international, multicentre, randomised, double-blind, placebo-controlled study over 12 weeks.

The purpose of this study is to demonstrate the beneficial effect of ivabradine on endothelial function in individuals with risk factors for cardiovascular disease and a resting HR * 75 bpm.

Evaluation of the subcutaneous administration of 30 mg of S78989 versus placebo and evaluation of the subcutaneous administration of 60mg of S78989 versus placebo, on the reduction of arterial wall inflammation in patients with marked atherosclerotic plaque inflammation.
A 28-weeks, randomized, double-blind, parallel-group, placebo controlled, international multicenter exploratory pilot study.

The objective of this study is to evaluate the effect of the 4 successive monthly subcutaneous administrations of 30 mg of gevokizumab (in part A) , as well as 60mg (in part B) of the protocol, versus placebo on the reduction of arterial wall…

A phase II study of ARA 290 as therapeutic strategy in no-option critical limb ischemia patients.

A proof of concept study to test whether ARA 290 improves wound healing and reduces neuropathic pain in no-option patients with CLI

The effect of vitamin K2 supplementation on cardiovascular risk markers.

The main objective is to investigate whether and at what dose vitamin K2 increases carboxylation of MGP. Secondary objective is to investigate the effect of vitamin K2 on markers of CVD (osteocalcin, blood lipids, inflammatory factors and insulin…

A randomised placebo-controlled trial of
fixed-dose combination medication in people
at raised risk of cardiovascular disease

To measure the efficacy (change in systolic blood pressure and LDL cholesterol) and tolerability of a polypill in individuals with raised risk of a cardiovascular event.

IMPACT:
Does the absolute magnitude of Platelet Inhibition inversely correlates with the number of TCD-detected microemboli during and after CAS in
asymptomatic patients undergoing carotid artery stenting prior to cardiac surgery who are being pre-treated with either a 300 mg or a 600 mg loading dose of clopidogrel?

Firstly, to investigate whether the absolute magnitude of Platelet Inhibition inversely correlates with the number of TCD-detected microemboli during and after CAS in patients who are being pre-treated with either a 300 mg or a 600 mg loading dose…

A randomized double blind placebo controlled ascending dose study to evaluate the effect of APL180 on endothelial function in patients with familial hypercholesterolemia

Assess whether APL180 can improve endothelial function in patients with Familial hypercholesterolemia

Allogeneic mesenchymal Stromal cells for Angiogenesis and neovascularization in no-option Ischemic Limbs

Primary Objective: To investigate whether intramuscular administration of allogeneic MSCs is safe and potentially effectiveSecondary Objective: To investigate the potential of various markers related to inflammation, angiogenesis, and…

A Randomised, Parallel, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Safety, Tolerability and Efficacy of AZD8233 Treatment in Participants with Hyperlipidaemia (SOLANO)

To assess the safety and tolerability of AZD8233 as compared with placebo in participants with hyperlipidaemia receiving maximally tolerated statin and/or ezetimibe therapy as defined by the investigator.

Inhibition of Mast cell Activation in AtheroScleroTic lesions using an Anti-IgE antibody approach (MAST-trial)

This study has been transitioned to CTIS with ID 2024-513581-19-00 check the CTIS register for the current data. The primary objective is, to determine whether short term anti-IgE treatment with an anti-IgE monoclonal antibody (omalizumab) can limit…

Impact of Triglyceride-Lowering on Inflammatory Activity in Patients with Hypertriglyceridemia

To study the impact of AKCEA-APOCIII-LRx on lipid and inflammatory measurements in the fasting and postprandial phase.

A Phase IIB, Randomized, Double blinded, Placebo controlled, Parallel
group Study to Evaluate the Efficacy and Safety of MEDI6570 in
Participants with a Prior Myocardial Infarction, Persistent Inflammation,
and Elevated N terminal Prohormone Brain Natriuretic Peptide

primaryTo evaluate the effect of MEDI6570 on non-calcified coronary atherosclerotic plaques compared with placebosecundaryTo evaluate the effect of MEDI6570 on a surrogate biomarker of HF compared with placeboTo evaluate the effect of MEDI6570 on…

Efficacy of Diltiazem to improve coronary microvascular dysfunction: A randomized clinical trial

This study has been transitioned to CTIS with ID 2024-512030-15-00 check the CTIS register for the current data. Our primary objective is to assess the effect of diltiazem on coronary microvascular function as assessed by coronary reactivity testing…

A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)

To evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of different doses and dosing regimens of ISIS 681257 for reduction of plasma Lp(a) levels in patients with hyperlipoproteinemia(a) and established CVD.To…

A randomized, placebo-controlled, double blind trial to investigate whether vitamin K2 can influence ongoing calcium deposition in patients with type 2 diabetes

The primary objective is to determine if MK-7 supplementation leads to stabilization or attenuation of ongoing calcium deposition, quantified by 18F- NaF PET/CT imaging in patients with type 2 diabetes.

Arterial wall inflammation measured with 18F-FDG PET/CT in patients with statin intolerance before and after treatment with a PCSK-9 inhibitor

In the present study, we set out to evaluate arterial wall inflammation in patients at increased CV-risk with statin-associated muscle symptoms (SAMS), precluding effective statin therapy. Following twelve weeks of treatment with PCSK9-Ab, the…